NO994103L - Reverse hydroksamatderivater som metallproteaseinhibitorer - Google Patents
Reverse hydroksamatderivater som metallproteaseinhibitorerInfo
- Publication number
- NO994103L NO994103L NO994103A NO994103A NO994103L NO 994103 L NO994103 L NO 994103L NO 994103 A NO994103 A NO 994103A NO 994103 A NO994103 A NO 994103A NO 994103 L NO994103 L NO 994103L
- Authority
- NO
- Norway
- Prior art keywords
- ethyl
- hydrogen
- tnf
- protease inhibitors
- sec
- Prior art date
Links
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 title 1
- 239000002184 metal Substances 0.000 title 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 title 1
- -1 3,3,3-trifluoro-n-propyl Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 102000035195 Peptidases Human genes 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 150000001261 hydroxy acids Chemical group 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Detergent Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3911297P | 1997-02-26 | 1997-02-26 | |
| PCT/EP1998/001015 WO1998038179A1 (en) | 1997-02-26 | 1998-02-24 | Reverse hydroxamate derivatives as metalloprotease inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO994103D0 NO994103D0 (no) | 1999-08-25 |
| NO994103L true NO994103L (no) | 1999-10-25 |
Family
ID=21903750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO994103A NO994103L (no) | 1997-02-26 | 1999-08-25 | Reverse hydroksamatderivater som metallproteaseinhibitorer |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1019386A1 (is) |
| JP (1) | JP2001513767A (is) |
| KR (1) | KR20000075681A (is) |
| AP (1) | AP9901631A0 (is) |
| AR (1) | AR013070A1 (is) |
| AU (1) | AU6822398A (is) |
| BR (1) | BR9807763A (is) |
| CA (1) | CA2281664A1 (is) |
| HR (1) | HRP980096A2 (is) |
| IS (1) | IS5159A (is) |
| NO (1) | NO994103L (is) |
| PE (1) | PE59199A1 (is) |
| PL (1) | PL335378A1 (is) |
| TR (1) | TR199902063T2 (is) |
| WO (1) | WO1998038179A1 (is) |
| ZA (1) | ZA981532B (is) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6235786B1 (en) | 1997-08-06 | 2001-05-22 | Abbott Laboratories | Reverse hydroxamate inhibitors of matrix metalloproteinases |
| US6294573B1 (en) | 1997-08-06 | 2001-09-25 | Abbott Laboratories | Reverse hydroxamate inhibitors of matrix metalloproteinases |
| GB2349884A (en) | 1998-02-07 | 2000-11-15 | British Biotech Pharm | Antibacterial agents |
| AU5688999A (en) * | 1998-08-26 | 2000-03-21 | Glaxo Group Limited | Formamide compounds as therapeutic agents |
| GB9818621D0 (en) * | 1998-08-26 | 1998-10-21 | Glaxo Group Ltd | Formamide compounds as therapeutic agents |
| AU5582899A (en) * | 1998-08-26 | 2000-03-21 | Glaxo Group Limited | Formamides as therapeutic agents |
| US6288261B1 (en) | 1998-12-18 | 2001-09-11 | Abbott Laboratories | Inhibitors of matrix metalloproteinases |
| US6329550B1 (en) | 1998-12-31 | 2001-12-11 | Aventis Pharmaceuticals Inc. | Amidomalonamides useful as inhibitors of MMP of matrix metalloproteinase |
| GB9918869D0 (en) * | 1999-08-10 | 1999-10-13 | British Biotech Pharm | Antibacterial agents |
| JP2003081838A (ja) * | 2001-09-11 | 2003-03-19 | Rohto Pharmaceut Co Ltd | グルコサミン製剤 |
| PE20030701A1 (es) | 2001-12-20 | 2003-08-21 | Schering Corp | Compuestos para el tratamiento de trastornos inflamatorios |
| US7011854B2 (en) | 2002-02-04 | 2006-03-14 | Alfama-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda | Method for treating a mammal by administration of a compound having the ability to release CO, compounds having the ability to release CO and pharmaceutical compositions thereof |
| EP1622617A2 (en) * | 2003-02-11 | 2006-02-08 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions based on anticholinergics and tace-inhibitors |
| JP2009533318A (ja) * | 2006-02-09 | 2009-09-17 | ザ バーナム インスティテュート | インスリン依存性糖尿病の処置のための膜１型マトリックスメタロプロテイナーゼのインヒビター |
| JP2011517313A (ja) | 2007-12-11 | 2011-06-02 | ビアメト ファーマシューティカルズ，インク． | 金属結合部分を標的化部分と組み合わせて使用する金属酵素阻害剤 |
| CN102046240B (zh) | 2008-03-25 | 2014-06-25 | 阿费克蒂斯药品公司 | 新的p2x7r拮抗剂及其应用 |
| WO2010118921A1 (en) | 2009-04-14 | 2010-10-21 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| WO2012110190A1 (en) | 2011-02-17 | 2012-08-23 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| US9163044B2 (en) | 2011-04-19 | 2015-10-20 | Alfama, Inc. | Carbon monoxide releasing molecules and uses thereof |
| WO2012163792A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| WO2012163456A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| ES2628634T3 (es) | 2011-07-21 | 2017-08-03 | Alfama, Inc. | Moléculas liberadoras de monóxido de carbono-rutenio y usos de las mismas |
| EP3860608A1 (en) | 2018-10-04 | 2021-08-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Egfr inhibitors for treating keratodermas |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9223904D0 (en) * | 1992-11-13 | 1993-01-06 | British Bio Technology | Inhibition of cytokine production |
| US6037472A (en) * | 1993-11-04 | 2000-03-14 | Syntex (U.S.A.) Inc. | Matrix metalloprotease inhibitors |
| DE69502378T2 (de) * | 1994-01-20 | 1998-10-01 | British Biotech Pharm | Metalloproteinaseinhibitoren |
| GB9514867D0 (en) * | 1995-07-20 | 1995-09-20 | British Biotech Pharm | Metalloproteinase inhibitors |
| ES2164264T3 (es) * | 1995-11-23 | 2002-02-16 | British Biotech Pharm | Inhibidores de metaloproteinasas. |
-
1998
- 1998-02-24 TR TR1999/02063T patent/TR199902063T2/xx unknown
- 1998-02-24 EP EP98913575A patent/EP1019386A1/en not_active Withdrawn
- 1998-02-24 KR KR1019997007747A patent/KR20000075681A/ko not_active Withdrawn
- 1998-02-24 JP JP53728498A patent/JP2001513767A/ja active Pending
- 1998-02-24 PL PL98335378A patent/PL335378A1/xx unknown
- 1998-02-24 BR BR9807763-5A patent/BR9807763A/pt not_active Application Discontinuation
- 1998-02-24 AU AU68223/98A patent/AU6822398A/en not_active Abandoned
- 1998-02-24 CA CA002281664A patent/CA2281664A1/en not_active Abandoned
- 1998-02-24 WO PCT/EP1998/001015 patent/WO1998038179A1/en not_active Ceased
- 1998-02-24 ZA ZA9801532A patent/ZA981532B/xx unknown
- 1998-02-24 HR HR60/039,112A patent/HRP980096A2/hr not_active Application Discontinuation
- 1998-02-24 AP APAP/P/1999/001631A patent/AP9901631A0/en unknown
- 1998-02-25 PE PE1998000138A patent/PE59199A1/es not_active Application Discontinuation
- 1998-02-25 AR ARP980100842A patent/AR013070A1/es unknown
-
1999
- 1999-08-20 IS IS5159A patent/IS5159A/is unknown
- 1999-08-25 NO NO994103A patent/NO994103L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2281664A1 (en) | 1998-09-03 |
| EP1019386A1 (en) | 2000-07-19 |
| JP2001513767A (ja) | 2001-09-04 |
| AR013070A1 (es) | 2000-12-13 |
| HRP980096A2 (en) | 1998-12-31 |
| AP9901631A0 (en) | 1999-09-30 |
| WO1998038179A1 (en) | 1998-09-03 |
| IS5159A (is) | 1999-08-20 |
| PE59199A1 (es) | 1999-06-24 |
| AU6822398A (en) | 1998-09-18 |
| ZA981532B (en) | 1999-08-24 |
| PL335378A1 (en) | 2000-04-25 |
| TR199902063T2 (xx) | 1999-12-21 |
| BR9807763A (pt) | 2000-02-22 |
| NO994103D0 (no) | 1999-08-25 |
| KR20000075681A (ko) | 2000-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO994103L (no) | Reverse hydroksamatderivater som metallproteaseinhibitorer | |
| MY107740A (en) | Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof | |
| MY136141A (en) | Novel hydantoin derivatives and pharmaceutical compositions useful as metalloproteinase inhibitors | |
| DK0641355T3 (da) | Anvendelse af sulfamatderivater som steroid-sulfatase-inhibitorer | |
| TR200100472T2 (tr) | Lipaz inhibitörleri ile sitozan içeren farmasötik bileşimler | |
| NO20051788L (no) | Hydantoinderivater og deres anvendelse som TACE-inhibitorer | |
| DK1052984T3 (da) | Antibakterielle midler | |
| CA2379747A1 (en) | Novel succinate derivative compounds useful as cysteine protease inhibitors | |
| CA2396738A1 (en) | Thiazole derivatives as active superoxide radical inhibitors | |
| AU7517400A (en) | N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent | |
| WO2004052853A3 (en) | Substituted 3-alkyl and 3-arylalkyl 1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) | |
| DK0810208T3 (da) | N-substituerede hydroxyethylamino sulfaminsyrederivater til anvendelse som inhibitorer af retrovirale proteaser | |
| CA2226894A1 (en) | 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives | |
| GB2412372A (en) | Pyrazine-based tubulin inhibitors | |
| NO986049L (no) | Matrise metallproteinaseinhibitorer | |
| MY128323A (en) | Thiazole derivatives for inhibition of cytokine production and of cell adhesion | |
| GB8622330D0 (en) | 4-substituted 6-alkylidenandrostene-3,17-dione derivatives | |
| SE7906638L (sv) | Peptidderivat | |
| IL161843A0 (en) | Use of 2-amino-4-pyridylmethyl-thiazoline dervatives as inhibitors of inducible no-synthase | |
| EP0655057A1 (en) | CYANOGUANIDINE AS A POTASS CHANNEL BLOCKER. | |
| NO983444L (no) | Benzo(c)kinolizin derivater, deres fremstilling og anvendelse som 5<alfa>-reduktaseinhibitorer | |
| CA2214386A1 (en) | Optically active thiazolidinone derivatives | |
| WO2001056353A3 (fr) | Nouveau procede de synthese de esters de la n-[(s)-1-carboxybutyl]-(s)-alanine et application a la synthese du perindopril | |
| DE69405760D1 (de) | 4-aza-pregnan-5-alpha-reductase isozym 1 inhibitoren | |
| YU78001A (sh) | Derivati 6-(((aril i heteroaril)oksi)metil) naftalen-2- karboksimidamida, njihovo dobijanje i terapeutska primena |